Sjogren's Syndrome Market to Register Sustainable Growth During the Study Period (2019-2032), Predicts DelveInsight | Key Players - Horizon Therapeutics, Dompe Farmaceutici, MorphoSys, Resolve Therapeutics, Novartis, Johnson & Johnson

The Sjogren's syndrome market is expected to be mainly driven by the increasing prevalence of the disease, along with the promising emerging pipeline therapies with a new mechanism of action, will fuel the Sjogren's syndrome market.

LAS VEGAS, Jan. 16, 2024 /PRNewswire/ -- DelveInsight's Sjogren's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Sjogren's syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Sjogren's Syndrome Market Report

• According to DelveInsight's analysis, the market size for Sjogren's syndrome across the 7MM is expected to grow with a significant CAGR by 2032.
• DelveInsight's analysis reveals that the overall diagnosed prevalent population of Sjogren's syndrome in the 7MM was reported as 3.2 million in 2022. 
• Globally, leading Sjogren's syndrome companies such as Horizon Therapeutics (Amgen), Dompe Farmaceutici, Sylentis, MorphoSys, Resolve Therapeutics, OSE Immunotherapeutics, Servier, Novartis, Johnson & Johnson, and others are developing novel Sjogren's syndrome drugs that can be available in the Sjogren's syndrome market in the coming years.
• The promising Sjogren's syndrome therapies in the pipeline include Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), VAY736, RSLV-132, Lusvertikimab (formerly OSE-127), CFZ533, Nipocalimab, and others.
• In November 2023, Amgen announced new data from its Phase II study evaluating dazodalibep, an investigational medicine, for the treatment of Sjogren's syndrome. As per the results, patients who transitioned from placebo todazodalibep experienced an improvement in their diseaseactivity from Day 169 (4.1-point reduction in total ESSDAI score) to Day 365 (6.3-point reduction). Dazodalibep was generally safe and well tolerated.

Discover which therapies are expected to grab the major Sjogren's syndrome market share @ Sjogren's Syndrome Market Report

Sjogren's Syndrome Overview

Sjogren's syndrome is an autoimmune condition marked by the infiltration of lymphocytes into exocrine glands, leading to dysfunction, particularly in the salivary and lacrimal glands. It is divided into primary and secondary types. The exact cause of the disease remains unclear, with current understanding suggesting a complex interplay of genetic defects, immune mechanisms, and viral infections. Diagnostic tools for primary Sjogren's syndrome encompass various serological, molecular, and histological biomarkers, such as autoantibodies, salivary gland features, histologic lesions, and laboratory abnormalities. Despite these, there is no singular clinical, laboratory, pathological, or radiological characteristic deemed a definitive gold standard for diagnosis or classification. Presently, labial salivary gland biopsy followed by histopathological evaluation is a commonly employed diagnostic method.

Sjogren's Syndrome Epidemiology Segmentation

The Sjogren's syndrome epidemiology section provides insights into the historical and current Sjogren's syndrome patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The Sjogren's syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Sjogren's Syndrome
• Type-specific Cases of Sjogren's Syndrome
• Gender-specific Cases of Sjogren's Syndrome 
• Severity-specific Cases of Sjogren's Syndrome Based on ESSDAI Score
• Antibody-specific Cases of Sjogren's Syndrome 
• Treated Cases of Sjogren's Syndrome 

Sjogren's Syndrome Treatment Market 

Currently, the therapeutic market for Sjogren's syndrome in the United States is predominantly influenced by local treatments, systemic approaches, and biological interventions. Local therapies encompass various options such as pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, among others. Systemic therapy relies on corticosteroids, hydroxychloroquine, and immunosuppressants. Disease-modifying antirheumatic drugs (DMARDs) like Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid are commonly employed. Rituximab holds significant prominence in biological therapy within the US market, complemented by the widespread use of TNF-alpha inhibitors, BAFF, and other emerging developments.

Typically, local therapy involves addressing sicca symptoms, with a focus on treating dry eyes. The primary approach to managing dry eyes is tear substitution therapy, which includes the use of high-viscosity eye drops and gels. This treatment is often complemented by oral mucolytic agents to dissolve mucus. For individuals experiencing severe or resistant keratoconjunctivitis sicca associated with Sjogren's syndrome, a brief course of topical anti-inflammatory agents such as cyclosporine may be necessary. In cases that do not respond well to standard treatments, alternatives like autologous serum eye drops and temporary punctal occlusion have been employed.

Medications with a widespread impact, known as secretagogues, such as pilocarpine and cevimeline, have received approval from the FDA for managing dry eyes and mouth in individuals with Sjogren's syndrome. Both these drugs function as muscarinic receptor agonists, leading to a temporary rise in salivary and lacrimal gland secretions in patients with some remaining functional glandular tissue. Noteworthy side effects associated with these medications encompass sweating, flushing, a compelling urge to urinate, and gastrointestinal discomfort, potentially constraining their clinical use.

To know more about Sjogren's syndrome treatment guidelines, visit @ Sjogren's Syndrome Management 

Sjogren's Syndrome Pipeline Therapies and Key Companies

• Dazodalibep (VIB4920): Horizon Therapeutics (Amgen)
• OXERVATE (cenegermin): Dompe Farmaceutici
• Tivanisiran (SYL1001): Sylentis
• VAY736: Novartis/MorphoSys
• RSLV-132: Resolve Therapeutics
• Lusvertikimab (formerly OSE-127): OSE Immunotherapeutics/Servier
• CFZ533: Novartis
• Nipocalimab: Johnson & Johnson

Learn more about the FDA-approved drugs for Sjogren's syndrome @ Drugs for Sjogren's Syndrome Treatment 

Sjogren's Syndrome Market Dynamics

The dynamics of Sjogren's syndrome are expected to change in the coming years. Considerable advances have been made in the past few years in the classification and treatment of Sjogren's syndrome. These progressions include enhanced understanding of disease mechanisms through advances in genetics, alongside ongoing exploration of the roles played by epigenetic and environmental factors.

Furthermore, many potential therapies are being investigated for the treatment of Sjogren's syndrome, and it is safe to predict that the treatment space will significantly impact the Sjogren's syndrome market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Sjogren's syndrome market in the 7MM.

However several factors may impede the growth of the Sjogren's syndrome market. Sjogren's syndrome is frequently underdiagnosed, primarily due to physicians not recognizing the manifold features of this systemic condition; thus, there is an ongoing necessity for robust studies that address key aspects of Sjogren's syndrome diagnosis, facing the challenge of demonstrating efficacy for the three symptom complexes—sicca, fatigue, and extra glandular manifestations.

Moreover, Sjogren's syndrome treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Sjogren's syndrome market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Sjogren's syndrome market growth.

Scope of the Sjogren's Syndrome Market Report

• Therapeutic Assessment: Sjogren's Syndrome current marketed and emerging therapies
• Sjogren's Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging Sjogren's Syndrome Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Sjogren's Syndrome Market Access and Reimbursement

Discover more about Sjogren's syndrome drugs in development @ Sjogren's Syndrome Clinical Trials

Table of Contents

Related Reports

Sjogren's Syndrome Pipeline

Sjogren's Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Sjogren's syndrome companies, including Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, among others.

Sjogren's Syndrome Epidemiology Forecast

Myocardial Infarction Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Sjogren's syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Systemic Lupus Erythematosus Market

Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, UCB Pharma, Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, among others.

Systemic Lupus Erythematosus Pipeline

Systemic Lupus Erythematosus Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SLE companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck KGaA, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com
+91-9650213330
www.delveinsight.com 

Logo - https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg